Navigation Links
Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
Date:8/28/2008

VIENNA, Austria, Aug. 28 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that its collaborator Merck & Co., Inc. has initiated a Phase II clinical trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infections. This randomized double blind, placebo controlled study aims to evaluate the safety and immunogenicity of the vaccine candidate in patients with end-stage kidney disease on hemodialysis. This trial start follows the initiation of a separate Phase II trial in December 2007.

Gerd Zettlmeissl, CEO of Intercell, commented "We are very pleased that our strategic partner Merck has chosen to initiate a further Phase II clinical trial. We look forward to continued progress of the program building on clinical data obtained so far."

The S. aureus vaccine candidate is based on a conserved protein antigen discovered by Intercell and licensed to Merck & Co., Inc. in 2004 on an exclusive worldwide basis. Merck is responsible for clinical development, manufacturing and marketing. Intercell is eligible to receive milestone payments and royalties on future net sales. In Phase I clinical trials the S. aureus candidate vaccine was shown to be immunogenic and generally well tolerated.

Hospital-acquired Infections

Hospital-acquired infections caused by bacteria are one of the major causes of death and serious illness. Intercell has embarked on a large scale, comprehensive and multi-target antigen identification program to contribute to vaccine efforts in this field. Besides Merck's S. aureus vaccine, based on an antigen identified by Intercell, Intercell is developing a vaccine against hospital-acquired infections caused by Pseudomonas aeruginosa (Phase II/III trial is expected to be initiated in 2008) and a Pneumococcus vaccine (Phase I trials planned for end 2008). Furthermore Intercell has ongoing pre-clinical programs for Enterococcus and Klebsiella vaccine discovery.

About S. aure
'/>"/>

SOURCE Intercell AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... ORANGEBURG, N.Y. , June 2, 2015 /PRNewswire/ ... products and solutions, today announced a series of ... customers about strategies to reduce the threat of ... with the US Centers for Disease Control and ... House,s National Strategy to Combat Antibiotic-Resistant Bacteria. ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( ... PharmaBiotech,s new report "Drug Delivery in Central ... to their offering. The delivery ... a challenge in the treatment of neurological disorders. ... or administered systematically (e.g., by intravenous injection) for ...
(Date:6/2/2015)... June 2, 2015 The Canadian Society for Vascular ... tests, treatments or procedures that are commonly ordered ... part of Choosing Wisely Canada.  The list identifies ... conversations between patients and physicians about what care ... for Vascular Surgery,s list identified the following five ...
Breaking Medicine Technology:PDI Partners with White House and Centers for Disease Control and Prevention (CDC) to Combat Antimicrobial Resistance 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 2As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 4
... July 28, 2011 Roka Bioscience, Inc. announced today ... equity financing, raising $20 million in new capital. The ... since the company,s formation in September 2009. The investor ... Advisors, New Enterprise Associates, Inc., TPG Biotech and Gen-Probe ...
... spending growth slowed from an estimated 5.3 percent in ... data released today by the Centers for Medicare and ... Researchers credit the slowdown in spending growth to pharmacy ... toward lower cost generic drugs. Pharmaceutical Care Management ...
Cached Medicine Technology:Roka Bioscience Completes $20 Million Series C Financing 2PCMA: Study Credits PBM Tools with Reducing Prescription Drug Spending Growth 2
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations and ... urgent care services in Los Angeles County. The ... California Board of Regents and the Exer Board of ... purchase a minority share of four existing Exer urgent ... Northridge and creates opportunity to grow and develop new, ...
(Date:6/2/2015)... New Jersey (PRWEB) June 02, 2015 ... (Horizon BCBSNJ) announced today that its Walking and Wellness ... Classic Presented by Acer, has raised another $3,000 for ... Natalie Gulbis undertook the challenge, recording 32,000 steps on ... at Stockton Seaview Hotel & Golf Club in Galloway ...
(Date:6/2/2015)... June 02, 2015 Bitscape Infotech today ... 2015 Microsoft Worldwide Small and Midsized Cloud Solutions Award. ... top Microsoft partners for demonstrating excellence in innovation and ... , “This comes as no surprise to us as ... year consecutively at worldwide level by Microsoft. We will ...
(Date:6/2/2015)... Radaris ” was featured on NewsWatch as part of its ... coolest applications on the market for iOS, Android, and Windows. ... the app review and shared with viewers can help users ... According to Psychology Today, humans are a curious species by ... is a part of human development. People are using the ...
(Date:6/2/2015)... 02, 2015 Tronics, a designer and ... growth strategy to benefit from the significant growth expected ... May 2015 Status of the MEMS Industry report, we ... reach $6.6B in 2020,” says Frederic Breussin, Business Unit ... , The analyst adds that “although the BioMEMS market ...
Breaking Medicine News(10 mins):Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 3Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:Tronics Aims to Benefit from Major Growth of Sensors and Related Technologies for Healthcare Applications 2
... finds city-dwelling females have more dense breasts, , , MONDAY, Nov. ... appear to have more dense breast tissue than their suburban ... potentially important because women with more dense breasts have a ... compared rural women from Greece to suburban and urban women ...
... a smoking gun, but its smoking-related, and its there ... deep in the lungs, caused by secondhand cigarette smoke. ... to nonsmokers that was long suspected, but not previously ... suggest that their findings may strengthen public health efforts ...
... For the first time, researchers have identified structural ... , The results of the study, conducted by ... in Charlottesville and The Childrens Hospital of Philadelphia in ... the Radiological Society of North America (RSNA). , Its ...
... clinical professor of neurology at Boston University School of ... Study, was recently awarded the Stroke Council Award from ... at the AHAs recent Scientific Sessions meeting in Orlando, ... encourages those who actively work to integrate stroke and ...
... at Yale and Cornell have created a modified chemotherapy ... of brain tumors by adding a water-soluble polymer ... the November-December issue of Bioconjugate Chemistry. , This approach ... than a centimeter, which may be sufficient to prevent ...
... Imaging, a,wholly owned subsidiary of Mercury Computer Systems, ... Siemens Medical Solutions to deliver advanced,3D visualization and ... Siemens will integrate Visage Imaging,s advanced 3D ... This unique thin client-based,image distribution solution will be ...
Cached Medicine News:Health News:Urban Women May Have Greater Breast Cancer Risk 2Health News:Urban Women May Have Greater Breast Cancer Risk 3Health News:Secondhand smoke damages lungs, MRIs show 2Health News:Novel MRI technique shows secondhand smoke damages lungs 2Health News:New method of drug delivery more effective at reaching brain tumors 2Health News:Visage Imaging Expands Availability of Its Advanced Visualization Offering 2Health News:Visage Imaging Expands Availability of Its Advanced Visualization Offering 3
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (240 style). Indications: Wide scleral bed. Outside diameter 31.7 mm....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: